In patients with Parkinson disease psychosis, treatment with pimavanserin has a lower risk for mortality compared with quetiapine or combination therapy.
The authors suggest that anxiety should be routinely evaluated in patients with Parkinson disease who experience freezing of gait.
As the neurodegenerative processes of Alzheimer disease and Parkinson disease are different, early cognitive impairment also present differently in these diseases.
Patients who felt the situation was “abnormal” were less likely to seek help. This trend was more common in patients with Parkinson disease than patients with dementia, although both described feeling “embarrassed or ashamed.”
Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson disease psychosis.
Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.
Mild traumatic brain injury is associated with increased risk of Parkinson disease among military veterans.
A new analytic model can now predict cognitive decline within 10 years of onset PD.
More specific biomarkers will be needed to differentiate between atypical parkinsonian disorders.
Levodopa pill can wear off, but a powdered version can help patients during off periods.